Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
IN8BIO, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
- Exchange
- nasdaq
- Notice
- extension granted
- Deficiency
- minimum bid price
- Rules
- 5550(a)(2)
Exact text from the filing
February 5, 2025, IN8bio, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq granted the Com
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.95
IN8BIO, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
- Exchange
- nasdaq
- Notice
- extension granted
- Deficiency
- minimum bid price
- Rules
- 5550(a)(2)
Exact text from the filing
February 5, 2025, IN8bio, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until August 4, 2025, to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”). In connection with the Extension Notice, the listing of the Company’s common stock was transferred from the Nasdaq Global Market to the Nasdaq Capi
View on SEC.gov